Pharmaceutical

EC approves CSL’s Andembry to stop hereditary angioedema attacks

CSL has received approval from the EC for Andembry (garadacimab) to prevent recurrent attacks of HAE in patients aged 12 years and above.

Feb 15, 2025 - 06:00
EC approves CSL’s Andembry to stop hereditary angioedema attacks
CSL has received approval from the EC for Andembry (garadacimab) to prevent recurrent attacks of HAE in patients aged 12 years and above.
Read the original article

Tags:

Previous Article

New Study Uncovers Significant Disparities in U.S. Health Care Spending Across C...

Next Article

DMD market expected to grow to $5.2bn in the 7MM by 2033

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Did you have Obamacare on your GOP debate bingo card?

Did you have Obamacare on your GOP debate bingo card?

Sep 28, 2023

FDA rejects Alvotech’s BLA for Stelara biosimilar

FDA rejects Alvotech’s BLA for Stelara biosimilar

Oct 13, 2023

Opinion: How do doctors’ personal political affiliations affect how they care for their patients?

Opinion: How do doctors’ personal political affiliation...

Jul 24, 2023